Research Notes
If longevity medicine gets real enough to sell, access becomes the real story.
Most public discussion drifts toward the glamorous scientific problem. Slower aging, cellular reprogramming, earlier diagnostics. Useful questions, but not the only ones. A better trail ran through enrollment criteria, employer benefits, trial participation, family offices, and the administrative machinery that decides whether a treatment counts as care or compensation.
